AbbVie (ABBV) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $443.24B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Robert A. Michael |
| IPO Date | 2013-01-02 | CAGR | 9.55% |
| Employees | 57,000 | Website | www.abbvie.com |
| Div. Yield | 2.72% | Payout Ratio | 187% |
| Buy Back Yield | 0.34% | Total Yield | 3.06% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $445.65B | P/E | 24.62 | Forward P/E | 15.41 | PEG | 1.04 |
| P/S | 6.88 | P/B | -66.75 | P/CF | 20.93 | P/FCF | 21.24 |
| Sales | $64.39B | Sales 1Y | 10.39% | Sales 3Y | 14.93% | Sales 5Y | 19.83% |
| EPS | $10.19 | EPS 1Y | 68.06% | EPS 3Y | -27.27% | EPS 5Y | -4.37% |
| Sales QoQ | 13.25% | EPS QoQ | 423.08% | Sales QoQ Avg | 2.79% | EPS QoQ Avg | 301.81% |
| Gross Margin | 74.1% | Operating Margin | 29.77% | Profit Margin | 9.82% | ROCE | 20.32% |
| ROA | 5% | ROE | -198% | Altman Z Score | 2.39 | Piotroski Score | 6 |
| Current Ratio | 0.8 | Quick Ratio | 0.68 | Cash Ratio | 0.22 | Op. CF Ratio | 0.09 |
| Debt/Equity | -10.95 | Debt/Assets | 0.53 | Lt Debt/Equity | -9.7 | Lt Debt/Cap. | 1.12 |
| Intrst Cov. | 6.73 | Inventory Turnover | 3.3 | Asset Turnover | 0.47 | Receivables Turnover | 5.16 |
| Enterprise Value | $445.65B | P/E Ratio | 24.62 |
| Forward P/E | 15.41 | PEG Ratio | 1.04 |
| P/S Ratio | 6.88 | P/B Ratio | -66.75 |
| P/CF Ratio | 20.93 | P/FCF Ratio | 21.24 |
| EPS | $10.19 | EPS Growth 1Y | 68.06% |
| EPS Growth 3Y | -27.27% | EPS Growth 5Y | -4.37% |
| Revenue Growth 1Y | 10.39% | Gross Margin | 0.74% |
| Operating Margin | 0.3% | Profit Margin | 0.1% |
| ROE | -1.98% | ROA | 0.05% |
| ROCE | 0.2% | Current Ratio | 0.8 |
| Quick Ratio | 0.68 | Cash Ratio | 0.22 |
| Debt/Equity | -10.95 | Interest Coverage | 6.73 |
| Altman Z Score | 2.39 | Piotroski Score | 6 |
AbbVie (ABBV) valuation & financials
AbbVie (ABBV) has a market capitalization of $443.24B and trades at a price-to-earnings ratio of 24.6. It operates in the Healthcare sector (Drug Manufacturers - General).
AbbVie's revenue grew +10.4% over the last year.
AbbVie's next earnings report is scheduled for July 31, 2026 before market open; analysts estimate EPS of $3.87.
AbbVie (ABBV) — frequently asked questions
When does AbbVie (ABBV) report earnings next?
AbbVie is expected to report earnings on July 31, 2026 before market open. Analysts estimate EPS of $3.87.
What is AbbVie's market cap?
AbbVie (ABBV) has a market capitalization of $443.24B.
What is ABBV's P/E ratio?
AbbVie trades at a price-to-earnings ratio of 24.6, with trailing twelve-month EPS of $10.19.
How fast is AbbVie growing?
AbbVie's revenue grew +10.4% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW) · Novartis (NVS)